CAMBRIDGE, UK--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures, today announced its cell therapy pipeline and declared its lead cell therapy candidate as it prepares to enter ...
A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
The disease-relevant mutation is engineered into bit.bio’s human ioWild Type TM cells using CRISPR/Cas9 gene editing. As disease model cells come from an identical human genetic background to ioWild ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results